Pharsight

Drugs that contain Treprostinil

1. Drug name - REMODULIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9604901 UNITED THERAP Process to prepare treprostinil, the active ingredient in Remodulin®
Dec, 2028

(6 years from now)

US9593066 UNITED THERAP Process to prepare treprostinil, the active ingredient in remodulin®
Dec, 2028

(6 years from now)

CN101903324B UNITED THERAP A Kind Of Preparation Of Active Composition In Remodulin Curved Latanoprost Is Improved Method
Dec, 2028

(6 years from now)

CN101903324A UNITED THERAP An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin
Dec, 2028

(6 years from now)

CN103274926B UNITED THERAP An Improved Method For Preparing Active Components In The Curved Remodulin
Dec, 2028

(6 years from now)

CN103274926A UNITED THERAP Process To Prepare Treprostinil, The Active Ingredient In Remodulin
Dec, 2028

(6 years from now)

IN287697B UNITED THERAP An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin
Dec, 2028

(6 years from now)

IN201003640P4 UNITED THERAP An Improved Process To Prepare Treprostinil,The Active Ingredient In Remodulin
Dec, 2028

(6 years from now)

EP2252570A1 UNITED THERAP An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin ®
Dec, 2028

(6 years from now)

EP2252570B1 UNITED THERAP An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin ®
Dec, 2028

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9199908 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs May, 2024

(1 year, 7 months from now)

US10076505 UNITED THERAP Inhalation formulations of Treprostinil Dec, 2024

(2 years from now)

US9713599 UNITED THERAP Parenteral formulations of treprostinil Dec, 2024

(2 years from now)

US10695308 UNITED THERAP Inhalation formulations of treprostinil Dec, 2024

(2 years from now)

US8653137 UNITED THERAP Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same Sep, 2028

(5 years from now)

US8658694 UNITED THERAP Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same Sep, 2028

(5 years from now)

US7999007 UNITED THERAP Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same Mar, 2029

(6 years from now)

Treatment: Administration of remodulin diluted for intravenous infusion with sterile water for injection or 0.9% sodium chloride injection prior to administration; A method of treating pulmonary hypertension comprising parenterally administering a formulation comprising a) 0.1 to 5% w/v of treprostinil or a pharmaceutically acceptable salt thereof and b) a citrate buffer; A method of treating a human patient suffering from pulmonary hypertension; Administration of remodulin diluted for intravenous infusion with sterile diluent for flolan or sterile diluent for epoprostenol sodium prior to administration

Dosage: INJECTABLE;IV (INFUSION), SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
1MG/ML INJECTABLE;IV (INFUSION), SUBCUTANEOUS Prescription
2.5MG/ML INJECTABLE;IV (INFUSION), SUBCUTANEOUS Prescription
5MG/ML INJECTABLE;IV (INFUSION), SUBCUTANEOUS Prescription
10MG/ML INJECTABLE;IV (INFUSION), SUBCUTANEOUS Prescription
20MG/ML INJECTABLE;IV (INFUSION), SUBCUTANEOUS Prescription

2. Drug name - TYVASO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9604901 UNITED THERAP Process to prepare treprostinil, the active ingredient in Remodulin®
Dec, 2028

(6 years from now)

US9593066 UNITED THERAP Process to prepare treprostinil, the active ingredient in remodulin®
Dec, 2028

(6 years from now)

CN101903324B UNITED THERAP A Kind Of Preparation Of Active Composition In Remodulin Curved Latanoprost Is Improved Method
Dec, 2028

(6 years from now)

CN101903324A UNITED THERAP An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin
Dec, 2028

(6 years from now)

CN103274926B UNITED THERAP An Improved Method For Preparing Active Components In The Curved Remodulin
Dec, 2028

(6 years from now)

CN103274926A UNITED THERAP Process To Prepare Treprostinil, The Active Ingredient In Remodulin
Dec, 2028

(6 years from now)

IN287697B UNITED THERAP An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin
Dec, 2028

(6 years from now)

IN201003640P4 UNITED THERAP An Improved Process To Prepare Treprostinil,The Active Ingredient In Remodulin
Dec, 2028

(6 years from now)

EP2252570A1 UNITED THERAP An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin ®
Dec, 2028

(6 years from now)

EP2252570B1 UNITED THERAP An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin ®
Dec, 2028

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10716793 UNITED THERAP Treprostinil administration by inhalation May, 2027

(4 years from now)

US10376525 UNITED THERAP Treprostinil administration by inhalation May, 2027

(4 years from now)

US9339507 UNITED THERAP Treprostinil administration by inhalation Mar, 2028

(5 years from now)

US9358240 UNITED THERAP Treprostinil administration by inhalation May, 2028

(5 years from now)

Treatment: Method of treating pulmonary hypertension by administering treprostinil or a salt thereof by inhalation using a device

Dosage: SOLUTION;INHALATION

More Information on Dosage
Strength Dosage Availability
0.6MG/ML SOLUTION;INHALATION Prescription

availability in other generic markets.

Click on the highlighted region to filter.